

## LIST OF TABLES

### 1.1 List of Tables

- Table 1: Initial Presenting Symptoms of Colorectal Cancer
- Table 2: TNM Classification System to Stage CRC
- Table 3: Stage Grouping for CRC
- Table 4: Stage II CRC Sub-Divisions
- Table 5: Stage III CRC Sub-Divisions
- Table 6: Stage IV CRC Sub-Divisions
- Table 7: Dukes System of CRC Classification
- Table 8: Treatment Guidelines for Colorectal Cancer
- Table 9: Surgical Options for Colorectal Cancer
- Table 10: Treatment Alternatives for CRC
- Table 11: Incident Cases of Colorectal Cancer, Ages  $\geq$ 40 Years, Men and Women, N, 2012-2019
- Table 12: Costs of CRC Diagnosis, Treatment and Care
- Table 13: CRC Screening Test Segmentation
- Table 14: Guaiac Fecal Occult Blood Tests Product Profile
- Table 15: Guaiac FOB Test SWOT Analysis, 2013
- Table 16: Immuno-FOB Tests
- Table 17: Product Profile - Lateral Flow Immunochemical Fecal Occult Blood Tests
- Table 18: Lateral Flow Immunochemical Fecal Occult Blood Tests SWOT Analysis, 2013
- Table 19: Product Profile - Veda Lab Easy Reader (Lateral Flow Immunochemical Fecal Occult Blood Tests with Readers)
- Table 20: Veda Lab Easy Reader (Lateral Flow Immunochemical Fecal Occult Blood Tests with Readers) SWOT Analysis, 2013
- Table 21: Fecal Occult Blood ELISA Products
- Table 22: Product Profile - Fecal Occult Blood ELISA
- Table 23: Immuno-FOB Test ELISA SWOT Analysis, 2013
- Table 24: Commercially Available Immuno-FOB Agglutination Test Systems
- Table 25: Product Profile - Immuno-FOB Agglutination Tests
- Table 26: Immuno-FOB Agglutination Tests SWOT Analysis, 2013
- Table 27: Key Mutations Associated with CRC
- Table 28: Key Stages of PCR Gene Test
- Table 29: Product Profile - PreGen Plus
- Table 30: PreGen Plus SWOT Analysis, 2013
- Table 31: Product Profile - K-RAS, B-RAF, PIK3CA Array
- Table 32: K-RAS, B-RAF, PIK3CA Array SWOT Analysis, 2013
- Table 33: Product Profile - Colonsentry
- Table 34: Colonsentry SWOT Analysis, 2013
- Table 35: Product Profile - Detector C 2.0
- Table 36: Detector C SWOT Analysis, 2013
- Table 37: Product Profile - ColoSure

Table 38: ColoSure SWOT Analysis, 2013  
Table 39: Product Profile - MS9  
Table 40: MS9 SWOT Analysis, 2013  
Table 41: Septin-9 CRC Screening Marketed Laboratory-Developed Tests  
Table 42: Product Profile - ColoVantage/Septin-9  
Table 43: ColoVantage/Septin-9 SWOT Analysis, 2013  
Table 44: Product Profile - Tumor M2-PK Stool Test/2-in-1 Quick Test  
Table 45: Tumor M2-PK Stool Test/2-in-1 Quick Test SWOT Analysis, 2013  
Table 46: Product Profile - Transferrin Assays  
Table 47: Transferrin Assays SWOT Analysis, 2013  
Table 48: Major Reasons for Non-compliance with CRC Screening  
Table 49: Correlation of Fecal Occult Blood Test with Neoplasia  
Table 50: CRC Screening Tests Pipeline, 2012  
Table 51: Product Profile - BST1 CRC Assay  
Table 52: BST1 CRC Assay SWOT Analysis, 2013  
Table 53: Product Profile - Cologic  
Table 54: Cologic SWOT Analysis, 2013  
Table 55: Product Profile - ColoGuard  
Table 56: ColoGuard SWOT Analysis, 2013  
Table 57: Product Profile - Colon Cancer BEC Test  
Table 58: Colon Cancer BEC Test SWOT Analysis, 2013  
Table 59: Product Profile - Colon MarCare Plex  
Table 60: Colon MarCare Plex SWOT Analysis, 2013  
Table 61: Product Profile - Colox  
Table 62: Colox SWOT Analysis, 2013  
Table 63: Product Profile - CRC Bacterial Signature Assay  
Table 64: CRC Bacterial Signature Assay SWOT Analysis, 2013  
Table 65: Product Profile - CRC Breath Test  
Table 66: CRC Breath Test SWOT Analysis, 2013  
Table 67: Product Profile - Epi proColon  
Table 68: Epi proColon Clinical Trials  
Table 69: Epi proColon SWOT Analysis, 2013  
Table 70: ExiQon MicroRNA Sensitivity and Specificity  
Table 71: Product Profile - ExiQon microRNA Test  
Table 72: ExiQon microRNA Test SWOT Analysis, 2013  
Table 73: Product Profile - Gemini CRC Biomarker Assay  
Table 74: Gemini CRC Biomarker Assay SWOT Analysis, 2013  
Table 75: Product Profile - GenomicTree Methylated DNA Test  
Table 76: GenomicTree Methylated DNA Test SWOT Analysis, 2013  
Table 77: Product Profile - Measure  
Table 78: Measure SWOT Analysis, 2013  
Table 79: Product Profile - Metabionics CRC Test  
Table 80: Metabionics CRC Test SWOT Analysis, 2013  
Table 81: Product Profile - miR-21 Test  
Table 82: miR-21 Test SWOT Analysis, 2013  
Table 83: Product Profile - Oncolite-CR

Table 84: Oncolite-CR SWOT Analysis, 2013  
Table 85: Product Profile - PanC-Dx  
Table 86: PanC-Dx SWOT Analysis, 2013  
Table 87: Healthcare Systems in the People's Republic of China  
Table 88: Healthcare Principles in the People's Republic of China  
Table 89: Key Mergers and Acquisitions during 2012-2013  
Table 90: Company Profile - Abbott Molecular  
Table 91: Abbott Molecular SWOT Analysis, 2013  
Table 92: Company Profile - Alere  
Table 93: Alere SWOT Analysis, 2013  
Table 94: Company Profile - Beckman Coulter  
Table 95: Beckman Coulter SWOT Analysis, 2013  
Table 96: Company Profile - Biomarcare Technologies  
Table 97: Biomarcare Technologies SWOT Analysis, 2013  
Table 98: Company Profile - Companion Dx  
Table 99: Companion Dx SWOT Analysis, 2013  
Table 100: Company Profile - Eiken Chemical  
Table 101: Eiken Chemical SWOT Analysis, 2013  
Table 102: Company Profile - Epigenomics  
Table 103: Epigenomics SWOT Analysis, 2013  
Table 104: Company Profile - Exact Sciences  
Table 105: Exact Sciences SWOT Analysis, 2013  
Table 106: Company Profile - ExiQon  
Table 107: ExiQon SWOT Analysis, 2013  
Table 108: Company Profile - Fujirebio (Miraca Holdings)  
Table 109: Fujirebio SWOT Analysis, 2013  
Table 110: Company Profile - GeneNews  
Table 111: GeneNews SWOT Analysis, 2013  
Table 112: Company Profile - GenomicTree  
Table 113: GenomicTree SWOT Analysis, 2013  
Table 114: Company Profile - Immunostics  
Table 115: Immunostics SWOT Analysis, 2013  
Table 116: Company Profile - Kyowa Medex (Kyowa Hakko Kirin Group)  
Table 117: Kyowa Medex SWOT Analysis, 2013  
Table 118: Company Profile - MDx Health  
Table 119: MDx Health SWOT Analysis, 2013  
Table 120: Company Profile - Merck Millipore  
Table 121: Merck Millipore SWOT Analysis, 2013  
Table 122: Company Profile - Metabionics  
Table 123: Metabionics SWOT Analysis, 2013  
Table 124: Company Profile - Mode Diagnostics  
Table 125: Mode Diagnostics SWOT Analysis, 2013  
Table 126: Company Profile - Oncocyte (Bio Time)  
Table 127: Oncocyte (Bio Time) SWOT Analysis, 2013  
Table 128: Company Profile - Quest Diagnostics  
Table 129: Quest Diagnostics SWOT Analysis, 2013

Table 130: Company Profile - R-Biopharm  
Table 131: R-Biopharm SWOT Analysis, 2013  
Table 132: Company Profile - Randox Laboratories  
Table 133: Randox Laboratories SWOT Analysis, 2013  
Table 134: Company Profile - ScheBo Biotech  
Table 135: Schebo Biotech SWOT Analysis, 2013  
Table 136: Company Profile - SciMarket Technologies  
Table 137: SciMarket Technologies SWOT Analysis, 2013  
Table 138: Company Profile - Siemens Healthcare  
Table 139: Siemens Healthcare SWOT Analysis, 2013  
Table 140: Company Profile - Signature Diagnostics  
Table 141: Signature Diagnostics SWOT Analysis, 2013  
Table 142: Company Profile - Sysmex  
Table 143: Sysmex SWOT Analysis, 2013  
Table 144: Company Profile - Veda Lab  
Table 145: Veda Lab SWOT Analysis, 2013  
Table 146: PreGen Plus Compared to Immuno-FOB Test  
Table 147: Potential Impacts of Restriction of Gene Patents  
Table 148: Major Events Affecting the APAC Regionl In-Vitro CRC Screening Test Market  
Table 149: Sales Forecasts for In-vitro CRC Screening Tests in the APAC Markets, 2010-2019  
Table 150: Forecasts for Numbers of In-vitro CRC Screening Tests in the APAC Region, 2010-2019  
Table 151: Sales Forecasts for In-vitro CRC Screening Tests in Japan, 2010-2019  
Table 152: Sales Forecasts for In-vitro CRC Screening Tests in China, 2010-2019  
Table 153: Sales Forecasts for In-vitro CRC Screening Tests in India, 2010-2019

## 1.2 List of Figures

Figure 1: Colorectal Cancer Staging  
Figure 2: APAC Trends in Colorectal Cancer Incidence, 2010-2019  
Figure 3: Total Costs of Colorectal Cancer to Society in Japan, 2010-2019  
Figure 4: Example of a Guaiac Fecal Occult Blood Card: Immunostics Hema-Screen  
Figure 5: Fecal Occult Blood Test Lateral Flow Device Architecture  
Figure 6: Biohit Colonview (example of immuno-FOB test)  
Figure 7: Beckman Coulter Hemocult-ICT (example of immuno-FOB test)  
Figure 8: Veda Labs Easy Reader Immuno-FOB Test LFD Reader  
Figure 9: OC-Hemodia Agglutination FOB Test (manually performed)  
Figure 10: OC-Sensor/Diana FOB Test Sample Cartridge  
Figure 11: OC-Sensor/Diana FOB Test Instrument  
Figure 12: Fujirebio HemSp/MagStream HT Magnetic Agglutination Reaction  
Figure 13: Sentinel Diagnostic Sentifob Instrument  
Figure 14: Alere CI5 NS-Plus Instrument  
Figure 15: Orion Diagnostics Quikread FOB Test and Instrument  
Figure 16: Basic PCR Process  
Figure 17: MS9 PCR Response Curve

Figure 18: Proposed ColoGuard Patient Stool Sample Collection Kit  
Figure 19: Exact Sciences Automated Sample Processing WorkStation  
Figure 20: Colox Kit Contents  
Figure 21: Measure Fecal Occult Blood Test  
Figure 22: PanC-Dx Multiplex Detection of CRC-specific Biomarker  
Figure 23: APAC Sales Forecast for In-vitro CRC Screening Tests (\$m), 2010-2019  
Figure 24: Forecast for Numbers of In-vitro CRC Screening Tests in APAC Region, 2010-2019  
Figure 25: APACShare of Fecal Occult Blood Tests, by Brand, 2012  
Figure 26: Japan Sales Forecast for In-vitro CRC Screening Tests (\$m), 2010-2019  
Figure 27: China Sales Forecast for In-vitro CRC Screening Tests (\$m), 2010-2019  
Figure 28: India Sales Forecast for In-vitro CRC Screening Tests (\$m), 2010-2019